One of the primary goals of developing therapy options for patients with MG is targeting the distinct phenotypes of the disease. For the patient population with refractory MG, three emerging monoclonal antibody–based therapies include rituximab, eculizumab, and belimumab.
Rituximab appears to work more effectively in patients with anti–MuSK-positive MG than in patients with anti–AChR-positive disease. Eculizumab, on the other hand, specifically targets complement activation involved in anti–AChR-positive MG and therefore has the most potential for efficacy in this patient subpopulation. To date, results from a randomized trial evaluating the efficacy of belimumab for patients with anti–MuSK-positive MG and anti–AChR-positive MG did not show statistically significantly different results in the treatment arm.
Learn more about medication use in patients with MG.
Medscape © 2021 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Raghav Govindarajan. Fast Five Quiz: Refractory Myasthenia Gravis - Medscape - Oct 13, 2021.